FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  STIGALL L. JEREMY
 2. Date of Event Requiring Statement (Month/Day/Year)
05/13/2022		 3. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [CLPT]
(Last)
(First)
(Middle)
C/O CLEARPOINT NEURO, INC., 120 S. SIERRA AVE., SUITE 100		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
GM, Biologics & Drug Delivery
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SOLANA BEACH, CA 92075		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock $ 25,683 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   (2) 08/20/2031 Common Stock 5,875 $ 16.71 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
STIGALL L. JEREMY
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
SOLANA BEACH, CA 92075		       GM, Biologics & Drug Delivery  

Signatures

/s/ Richard F. Mattern by Power of Attorney for Jeremy L. Stigall 05/19/2022
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes 22,563 shares of restricted stock, 19,274 shares of which are unvested as of the date of this filing.
(2) The option agreement provides that the option becomes exercisable twenty percent (20%) on the first anniversary of the option's grant date with the remaining eighty percent (80%) becoming exercisable in two equal annual installments on the second and third anniversaries, respectively, of the option's grant date. The option was granted on August 20, 2021.
 
Remarks:
Power of Attorney is attached to this Form 3 as Exhibit 24.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.